Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

  • End date
    Dec 7, 2024
  • participants needed
  • sponsor
    C4 Therapeutics, Inc.
Updated on 22 August 2021
bone marrow transplant
multiple myeloma
measurable disease
bone marrow procedure
progressive disease
chemotherapy regimen
follicular lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
mantle cell lymphoma
antibody therapy
t-cell lymphoma
large b-cell lymphoma
refractory non-hodgkin's lymphoma


The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone.

Condition Multiple Myeloma, Lymphoma, Lymphoproliferative Disorder, multiple myeloma (mm)
Treatment Dexamethasone Oral, CFT7455
Clinical Study IdentifierNCT04756726
SponsorC4 Therapeutics, Inc.
Last Modified on22 August 2021


Yes No Not Sure

Inclusion Criteria

Be willing and able to provide signed informed consent for the trial
Age 18 years at the time of signed consent
Have histologically or cytologically-confirmed NHL or MM that is r/r disease and must not be candidates for regimens known to provide clinical benefit to be eligible for the study
MM subject must have a documented diagnosis of MM and measurable disease at enrollment. Measurable disease is defined as
M-protein 0.5g/dL by Serum Protein Electrophoresis (sPEP) or
mg/24-hour urine collection by Urine Protein Electrophoresis (uPEP) or
Serum Free Light Chain (FLC) levels >100 mg/L involved light chain and an abnormal kappa/lambda (/) ratio in subjects without measurable serum or urine M-protein or
For subjects with immunoglobulin class A (IgA), myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level 0.50g/dL
Prior treatments for MM subjects must have the following
Received at least 3 prior anti-myeloma regimens including at least 2 consecutive cycles of lenalidomide, pomalidomide, a proteasome inhibitor a glucocorticoid and an anti-CD38 antibody (induction with or without a bone marrow transplant with or without maintenance therapy is considered one regimen)
Refractory disease defined as disease that is nonresponsive to therapy (failure to achieve minimal response or development of progressive disease) or disease progression within 60 days from the last dose of their last myeloma therapy
NHL subjects must have documented diagnosis of NHL and measurable disease defined by measurable disease (consistent with Lugano classification) defined as at least one lesion that can be accurately measured in at least two dimensions with PET-CT, documented within 4 weeks of their projected cycle one day one (C1D1) visit. Minimum measurement must be >15 mm in the longest diameter
NHL subjects must have received the following regarding prior therapy
Peripheral T-cell Lymphoma: At least one prior line containing alkylator-based chemotherapy. Note: For subjects with Anaplastic Large Cell Lymphoma (ALCL), the subject must also have received CD30 antibody therapy
Mantle Cell Lymphoma: 2 lines of therapy, including CD20 antibody and alkylator chemotherapy, and a Bruton's tyrosine kinase (BTK) inhibitor
Follicular Lymphoma: 2 lines of therapy, including CD20 antibody therapy and alkylator chemotherapy
Diffuse Large B-cell Lymphoma: 2 lines of therapy, including prior CD20 antibody therapy, and has received prior autologous bone marrow transplant (or is ineligible for bone marrow transplant)
Other NHL: Subjects must have been treated with all standard of care therapies available to the subject which, in the assessment of the investigator, may be beneficial to the subject
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies
A woman of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MIU/mL and estradiol < 40 pg/mL (<147 pmol/L) must be obtained]
Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods specified in the study protocol if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrollment
Agree to having ongoing pregnancy tests during the study and after discontinuation of the study
A male participant must have either had a prior vasectomy or agree to use a condom during the treatment period and for at least 90 days after the last dose of study treatment

Exclusion Criteria

Presence of central nervous system (CNS) disease
Has received prior radiotherapy within 2 weeks of start of study treatment
Have active pneumonitis
Have any of the following
Non-secretory or oligosecretory MM
Plasma cell leukemia
Systemic light chain amyloidosis
Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome
Lymphoblastic lymphoma
Mycosis fungoides
Sezary syndrome
Primary cutaneous T-cell lymphomas
Primary CNS lymphoma
B-cell or T-cell prolymphocytic leukemia
Subjects with a peripheral neuropathy Grade 2
Known malignancy other than study indication that is progressing or has required treatment within the past three years
Received live, attenuated vaccine within four weeks of first dose
Known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority
Subjects with positive test for Hepatitis B surface (HBS-Ag) or Hepatitis B core (HBc) antigen
Subjects with positive test for hepatitis C (HCV) infection are excluded regardless of viral load. If hepatitis C antibody test is positive, a confirmatory test should be performed. If the test is negative, subject is eligible for this trial
Concurrent administration of strong CYP3A modulators
Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
Subjects on proton pump inhibitors (PPIs). The last dose of PPIs must be administered seven days prior to administration of study drug. Antacids are acceptable when administered in a staggered dosing manner with CFT7455
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note